La chaîne d'options affiche les données clés des options sur actions de Semler Scientific à différents prix d'exercice et dates d'expiration. Les traders utilisent ces informations pour analyser les transactions potentielles et évaluer le sentiment du marché pour Semler Scientific..

Semler Scientific (NASDAQ:SMLR) Stock, Chaîne d'Options

Semler Scientific

Semler Scientific Inc is a United States based company that is engaged in providing technology solutions to improve the clinical effectiveness and efficiency of healthcare providers. It focuses on developing, manufacturing, and marketing proprietary products and services that assist customers, including insurance plans, physicians, and risk assessment groups, in evaluating and treating chronic diseases. The company markets its vascular-testing product under the QuantaFlo brand, which is a four-minute in-office blood flow test.

Semler Scientific Inc

ERIC SEMLER, Director at Semler Scientific (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SMLR#NASDAQ">SMLR</a>), disclosed an insider purchase on November 12, based on a new SEC filing.
What Happened: SEMLER made a significant move by purchasing 50,000 shares of Semler Scientific as reported in a Form 4 filing with the <a href="https://www.sec.gov/Archives/edgar/data/0001554859/000110465924116129//Archives/edgar/data/1554859/000110465924116129/0001104659-24-116129-index.htm">U.S. Securities and Exchange Commission</a>. The transaction's total worth stands at $1,896,500.
The latest market snapshot at Tuesday morning reveals Semler Scientific shares down by 0.46%, trading at $51.9.
<h3>All You Need to Know About Semler Scientific</h3>
Semler Scientific Inc is a United States based company that is engaged in providing technology solutions to improve the clinical effectiveness and efficiency of healthcare providers. It focuses on developing, manufacturing, and marketing proprietary products and services that assist customers, including insurance plans, physicians, and risk assessment groups, in evaluating and treating chronic diseases. The company markets its vascular-testing product under the QuantaFlo brand, which is a four-minute in-office blood flow test.
<h3>Unraveling the Financial Story of Semler Scientific</h3>
Revenue Challenges: Semler Scientific's revenue growth over 3 months faced difficulties. As of 30 September, 2024, the company experienced a decline of approximately -17.19%. This indicates a decrease in top-line earnings. As compared to its peers, the revenue growth lags behind its industry peers. The company achieved a growth rate lower than the average among peers in Health Care sector.
Exploring Profitability:
<ul>
<li>
Gross Margin: The company maintains a high gross margin of 91.44%, indicating strong cost management and profitability compared to its peers.
</li>
<li>
Earnings per Share (EPS): Semler Scientific's EPS is notably higher than the industry average. The company achieved a positive bottom-line trend with a current EPS of 0.8.
</li>
</ul>
Debt Management: Semler Scientific's debt-to-equity ratio is below industry norms, indicating a sound financial structure with a ratio of 0.0.
Analyzing Market Valuation:
<ul>
<li>
Price to Earnings (P/E) Ratio: The P/E ratio of 25.47 is lower than the industry average, implying a discounted valuation for Semler Scientific's stock.
</li>
<li>
Price to Sales (P/S) Ratio: With a relatively high Price to Sales ratio of 6.85 as compared to the industry average, the stock might be considered overvalued based on sales performance.
</li>
<li>
EV/EBITDA Analysis (Enterprise Value to its Earnings Before Interest, Taxes, Depreciation &amp; Amortization): Indicated by a lower-than-industry-average EV/EBITDA ratio of 17.64, the company suggests a potential undervaluation, which might be advantageous for value-focused investors.
</li>
</ul>
Market Capitalization Analysis: Positioned below industry benchmarks, the company's market capitalization faces constraints in size. This could be influenced by factors such as growth expectations or operational capacity.
<a href="https://www.schwab.com/brokerage?aff=XEC">Now trade stocks online commission free with Charles Schwab, a trusted and complete investment firm.</a>
<h3>Delving Into the Significance of Insider Transactions</h3>
Insider transactions are not the sole determinant of investment choices, but they are a factor worth considering.
Considering the legal perspective, an "insider" is defined as any officer, director, or beneficial owner holding more than ten percent of a company's equity securities, according to Section 12 of the Securities Exchange Act of 1934. This includes executives in the c-suite and major hedge funds. These insiders are mandated to disclose their transactions through a Form 4 filing, to be submitted within two business days of the transaction.
Pointing towards optimism, a company insider's new purchase signals their positive anticipation for the stock to rise.
Nevertheless, insider sells may not necessarily indicate a bearish view and can be influenced by various factors.
<h3>Unlocking the Meaning of Transaction Codes</h3>
When dissecting transactions, the focal point for <a href="https://www.benzinga.com/money/investing-tools">investors</a> is often those occurring in the open market, meticulously detailed in Table I of the Form 4 filing. A P in Box 3 denotes a purchase, while S signifies a sale. Transaction code C indicates the conversion of an option, and transaction code A denotes a grant, award, or other acquisition of securities from the company.
<a href="https://www.benzinga.com/sec/insider-trades/search/index?company_cik=0001554859">Check Out The Full List Of Semler Scientific's Insider Trades.</a>
Insider Buying Alert: Profit from C-Suite Moves
Benzinga Edge reveals every insider trade in real-time. Don't miss the next big stock move driven by insider confidence. Unlock this ultimate sentiment indicator now. <a href="https://www.benzinga.com/premium/ideas/benzinga-edge-checkout/?t=Be8be9arja3be22in8&amp;utm_source=benzinga-insights">Click here for access</a>.
This article was generated by Benzinga's automated content engine and reviewed by an editor.

News

Insider Trades

Trading Ideas

SMLR

Director Of Semler Scientific Purchased $1.90M In Stock

In a new SEC filing on November 12, it was revealed that Murphy-Chutorian, CEO at Semler Scientific (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SMLR#NASDAQ">SMLR</a>), executed a significant exercise of company stock options.
What Happened: A Form 4 filing with the <a href="https://www.sec.gov/Archives/edgar/data/0001554859/000110465924116136//Archives/edgar/data/1554859/000110465924116136/0001104659-24-116136-index.htm">U.S. Securities and Exchange Commission</a> on Tuesday revealed that Murphy-Chutorian, CEO at Semler Scientific in the Health Care sector, exercised stock options for 100,000 shares of SMLR stock. The exercise price of the options was $2.33 per share.
As of Tuesday morning, Semler Scientific shares are up by 5.76%, with a current price of $55.14. This implies that Murphy-Chutorian's 100,000 shares have a value of $5,281,140.
<h3>Get to Know Semler Scientific Better</h3>
Semler Scientific Inc is a United States based company that is engaged in providing technology solutions to improve the clinical effectiveness and efficiency of healthcare providers. It focuses on developing, manufacturing, and marketing proprietary products and services that assist customers, including insurance plans, physicians, and risk assessment groups, in evaluating and treating chronic diseases. The company markets its vascular-testing product under the QuantaFlo brand, which is a four-minute in-office blood flow test.
<h3>Semler Scientific: Delving into Financials</h3>
Revenue Challenges: Semler Scientific's revenue growth over 3 months faced difficulties. As of 30 September, 2024, the company experienced a decline of approximately -17.19%. This indicates a decrease in top-line earnings. As compared to its peers, the revenue growth lags behind its industry peers. The company achieved a growth rate lower than the average among peers in Health Care sector.
Holistic Profitability Examination:
<ul>
<li>
Gross Margin: The company sets a benchmark with a high gross margin of 91.44%, reflecting superior cost management and profitability compared to its peers.
</li>
<li>
Earnings per Share (EPS): Semler Scientific's EPS is a standout, portraying a positive bottom-line trend that exceeds the industry average with a current EPS of 0.8.
</li>
</ul>
Debt Management: Semler Scientific's debt-to-equity ratio is below the industry average at 0.0, reflecting a lower dependency on debt financing and a more conservative financial approach.
Valuation Overview:
<ul>
<li>
Price to Earnings (P/E) Ratio: The current P/E ratio of 25.47 is below industry norms, indicating potential undervaluation and presenting an investment opportunity.
</li>
<li>
Price to Sales (P/S) Ratio: With a higher-than-average P/S ratio of 6.85, Semler Scientific's stock is perceived as being overvalued in the market, particularly in relation to sales performance.
</li>
<li>
EV/EBITDA Analysis (Enterprise Value to its Earnings Before Interest, Taxes, Depreciation &amp; Amortization): With an EV/EBITDA ratio lower than industry averages at 17.64, Semler Scientific could be considered undervalued.
</li>
</ul>
Market Capitalization Perspectives: The company's market capitalization falls below industry averages, signaling a relatively smaller size compared to peers. This positioning may be influenced by factors such as perceived growth potential or operational scale.
<a href="https://www.schwab.com/brokerage?aff=XEC">Now trade stocks online commission free with Charles Schwab, a trusted and complete investment firm.</a>
<h3>Uncovering the Importance of Insider Activity</h3>
Emphasizing the importance of a comprehensive approach, considering insider transactions is valuable, but it's crucial to evaluate them in conjunction with other investment factors.
In legal terms, an "insider" refers to any officer, director, or beneficial owner of more than ten percent of a company's equity securities registered under Section 12 of the Securities Exchange Act of 1934. This can include executives in the c-suite and large hedge funds. These insiders are required to let the public know of their transactions via a Form 4 filing, which must be filed within two business days of the transaction.
When a company insider makes a new purchase, that is an indication that they expect the stock to rise.
Insider sells, on the other hand, can be made for a variety of reasons, and may not necessarily mean that the seller thinks the stock will go down. 
<h3>Unlocking the Meaning of Transaction Codes</h3>
Surveying the realm of stock transactions, <a href="https://www.benzinga.com/money/investing-tools">investors</a> often give prominence to those unfolding in the open market, systematically detailed in Table I of the Form 4 filing. A P in Box 3 indicates a purchase, while S signifies a sale. Transaction code C denotes the conversion of an option, and transaction code A denotes a grant, award, or other acquisition of securities from the company.
<a href="https://www.benzinga.com/sec/insider-trades/search/index?company_cik=0001554859">Check Out The Full List Of Semler Scientific's Insider Trades.</a>
Insider Buying Alert: Profit from C-Suite Moves
Benzinga Edge reveals every insider trade in real-time. Don't miss the next big stock move driven by insider confidence. Unlock this ultimate sentiment indicator now. <a href="https://www.benzinga.com/premium/ideas/benzinga-edge-checkout/?t=Be8be9arja3be22in8&amp;utm_source=benzinga-insights">Click here for access</a>.
This article was generated by Benzinga's automated content engine and reviewed by an editor.

Options Exercise: Douglas Murphy-Chutorian At Semler Scientific Realizes $5.28M

<h3>Gainers</h3>
<ul>
<li>Bluejay Diagnostics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/BJDX#NASDAQ">BJDX</a>) shares moved upwards by 147.2% to $0.18 during Tuesday's regular session. The company's market cap stands at $2.9 million. </li>
<li>Bionomics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/BNOX#NASDAQ">BNOX</a>) shares moved upwards by 143.67% to $0.47. The market value of their outstanding shares is at $6.1 million. </li>
<li>ZyVersa Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ZVSA#NASDAQ">ZVSA</a>) shares increased by 35.16% to $2.46. The company's market cap stands at $2.6 million. </li>
<li>Semler Scientific (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SMLR#NASDAQ">SMLR</a>) shares moved upwards by 29.29% to $38.75. The market value of their outstanding shares is at $270.9 million. As per the news, the Q3 earnings report came out yesterday. </li>
<li>Inotiv (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/NOTV#NASDAQ">NOTV</a>) stock increased by 19.42% to $2.09. The company's market cap stands at $54.3 million. </li>
<li>Athira Pharma (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ATHA#NASDAQ">ATHA</a>) stock increased by 18.29% to $0.76. The market value of their outstanding shares is at $29.0 million. </li>
</ul>
<h3>Losers</h3>
<ul>
<li>Verrica Pharmaceuticals (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/VRCA#NASDAQ">VRCA</a>) shares decreased by 39.9% to $0.86 during Tuesday's regular session. The company's market cap stands at $36.6 million. As per the news, the Q3 earnings report came out yesterday. </li>
<li>Nuwellis (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/NUWE#NASDAQ">NUWE</a>) stock declined by 29.9% to $1.97. The market value of their outstanding shares is at $3.6 million. </li>
<li>ATI Physical Therapy (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/ATIP#NYSE">ATIP</a>) stock fell 20.49% to $4.09. The market value of their outstanding shares is at $18.0 million. The company's, Q3 earnings came out yesterday. </li>
<li>Bioventus (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/BVS#NASDAQ">BVS</a>) shares decreased by 19.06% to $11.1. The company's market cap stands at $722.1 million. The company's, Q3 earnings came out today. </li>
<li>Sana Biotechnology (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SANA#NASDAQ">SANA</a>) shares decreased by 18.09% to $3.08. The market value of their outstanding shares is at $685.1 million. </li>
<li>LakeShore Biopharma (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/LSB#NASDAQ">LSB</a>) stock declined by 15.56% to $1.9. The market value of their outstanding shares is at $36.2 million. 
See Also: <a href="http://www.benzinga.com/money/best-healthcare-stocks/" title="www.benzinga.com/money/best-healthcare-stocks/">www.benzinga.com/money/best-healthcare-stocks/</a></li>
</ul>
This article was generated by Benzinga's automated content engine and reviewed by an editor.

Movers

ATHA

ATIP

BJDX

BNOX

NOTV

NUWE

SANA

VRCA

ZVSA

12 Health Care Stocks Moving In Tuesday's Intraday Session

WIIM

Semler Scientific shares are trading higher after the company reported better-than-expected Q3 financial results.

Semler Scientific (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SMLR#NASDAQ">SMLR</a>) reported quarterly earnings of $0.72 per share which beat the analyst consensus estimate of $0.37 by 94.59 percent. This is a 1.41 percent increase over earnings of $0.71 per share from the same period last year. The company reported quarterly sales of $13.512 million which beat the analyst consensus estimate of $13.100 million by 3.15 percent. This is a 17.19 percent decrease over sales of $16.316 million the same period last year.

Earnings

Earnings Beats

Semler Scientific Q3 2024 GAAP EPS $0.72 Beats $0.37 Estimate, Sales $13.512M Beat $13.100M Estimate

Michael Saylor&#8216;s declaration that &#8220;MicroStrategy (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MSTR#NASDAQ">MSTR</a>) is the public equity play on Bitcoin maximalism&#8221; aptly defines the company&#8217;s pioneering approach in <a href="https://www.benzinga.com/markets/cryptocurrency/24/10/41585530/asias-microstrategy-metaplanet-buys-another-10-4m-in-bitcoin-exceeds-1-000-btc-holdings">corporate Bitcoin holdings</a>.
Saylor highlighted the company&#8217;s strategy in a post on X on Thursday:
<figure class="wp-block-embed is-type-rich is-provider-twitter wp-block-embed-twitter"> 
<div class="wp-block-embed__wrapper">
<blockquote class="twitter-tweet" data-width="500" data-dnt="true">MicroStrategy is the public equity play on <a href="https://twitter.com/hashtag/Bitcoin?src=hash&amp;ref_src=twsrc%5Etfw">#Bitcoin</a> Maximalism. <a href="https://t.co/96lpcdN5Zi">pic.twitter.com/96lpcdN5Zi</a>
&mdash; Michael Saylor&#x26a1;&#xFE0F; (@saylor) <a href="https://twitter.com/saylor/status/1852116357724475532?ref_src=twsrc%5Etfw">October 31, 2024</a></blockquote>
<script async src="https://platform.twitter.com/widgets.js" charset="utf-8"></script></div>
</figure>
How MicroStrategy Leverages Bitcoin: MicroStrategy has not only redefined its own treasury strategy but also set a model that other companies are now beginning to emulate.
The firm's Bitcoin (CRYPTO: <a class="ticker" href="https://www.benzinga.com/quote/btc/usd">BTC</a>)-centric approach, producing returns well above the S&amp;P 500, has led to notable shifts in corporate treasury strategies worldwide.
Since MicroStrategy's pivot in 2020, the company has consistently purchased Bitcoin, achieving an annual average return of 44%, significantly higher than the S&amp;P 500&#8217;s 12% <a href="https://www.benzinga.com/markets/cryptocurrency/24/09/40776328/microstrategys-bitcoin-strategy-has-outperformed-every-s-p-500-company-and-even-nvidia-sin">during the same period</a>, Saylor told CNBC in a recent interview.
Notably, MicroStrategy's strategy yielded an 825% return, outperforming even Nvidia&#8217;s 821% rise, further showcasing the power of its Bitcoin holdings. 
The firm continues its role as a &#8220;cash cow&#8221; in the software sector while embracing Bitcoin as a primary treasury asset, according to Saylor. 
This dual model allows MicroStrategy to finance Bitcoin acquisitions through securitized instruments like convertible bonds, presenting investors with exposure to Bitcoin at a reduced volatility level.
<figure class="wp-block-image size-full"><a href="https://www.benzinga.com/events/digital-assets/ "><img loading="lazy" decoding="async" width="300" height="250" src="https://editorial-assets.benzinga.com/wp-content/uploads/2024/03/29155259/905735A6-57D3-4874-9AA1-75D037842DB3-2.gif" alt="Benzinga Future of Digital Assets conference" class="wp-image-270548" /></a></figure>
Also Read: <a href="https://www.benzinga.com/markets/cryptocurrency/24/10/41667204/what-coin-should-i-buy-binance-founder-changpeng-zhao-shares-anecdotes-from-4-month-prison">&#8216;What Coin Should I Buy?&#8217;—Binance Founder Changpeng Zhao Shares Anecdotes From 4-Month Prison Stint</a>
Who&#8217;s Following The MicroStrategy Apporach: The bold move has stirred interest among other companies, especially as MicroStrategy recently announced its acquisition of 25,889 BTC in Q3, valued at $1.6 billion.
The strategy brought the company's total holdings to 252,220 BTC, worth approximately $18.23 billion, positioning it as a prominent advocate for using Bitcoin as a <a href="https://www.benzinga.com/markets/cryptocurrency/24/10/41646462/michael-saylor-says-bitcoin-remedy-to-fix-unhealthy-balance-sheets-as-microstrategy-unveil">hedge in uncertain economic times.</a> 
Despite the risks associated with Bitcoin's volatility, Saylor emphasized that Bitcoin "fixes the balance sheet," offering liquidity and resilience to a firm's finances. 
MicroStrategy plans to raise an additional $42 billion through equity and debt financing in the coming years to further its Bitcoin acquisitions, reinforcing its belief in Bitcoin's long-term value.
Following MicroStrategy's example, companies like Cathedra Bitcoin (OTC:<a class="ticker" href="https://www.benzinga.com/stock/CBTTF#OTC">CBTTF</a>), Metaplanet and Semler Scientific (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SMLR#NASDAQ">SMLR</a>) have implemented similar Bitcoin-centered approaches.
Cathedra Bitcoin, listed on the TSX Venture Exchange, has transitioned its operations from mining to data management to sustainably increase its Bitcoin holdings. 
Meanwhile, Metaplanet has prioritized Bitcoin growth month-over-month, achieving a 587% stock increase this year, reflecting a shift toward maximizing Bitcoin <a href="https://www.benzinga.com/markets/cryptocurrency/24/09/40942247/microstrategys-bitcoin-playbook-is-becoming-a-hit-among-companies-but-theres-a-catch">reserves to enhance shareholder value.</a>
This shift, coined the &#8220;<a href="https://www.benzinga.com/startups/24/10/41434521/tesla-quietly-transfers-765-million-in-bitcoin-putting-musks-cryptocurrency-strategy-under-intense-s">maximize Bitcoin per share</a>&#8221; approach, is becoming a compelling alternative for firms seeking inflation hedges and asset stability.
For those interested in the ongoing impact of this strategy on the digital finance landscape, Benzinga's <a href="https://www.benzinga.com/events/digital-assets/agenda/">Future of Digital Assets</a> event on Nov. 19 will be a pivotal platform to explore further, with discussions on corporate adoption and innovations in digital assets expected.
Read Next: 
<ul>
<li><a href="https://www.benzinga.com/markets/cryptocurrency/24/10/41662414/donald-trump-wishes-bitcoiners-happy-birthday-vows-to-end-kamalas-war-on-crypto-as-world-l">Donald Trump Wishes Bitcoiners &#8216;Happy Birthday&#8217;, Vows To &#8216;End Kamala&#8217;s War On Crypto&#8217; As World Liberty Financial Falls Way Short Of Fundraising Goal</a></li>
</ul>
Image: Shutterstock

Coverage of Bitcoin, Etherum, Ripple and all the latest digital currencies.

Cryptocurrency

$BTC

CBTTF

MSTR

Michael Saylor Calls MicroStrategy The 'Public Equity Play On Bitcoin Maximalism': Here's Who's Following This Approach

As Bitcoin (CRYPTO: <a class="ticker" href="https://www.benzinga.com/quote/btc/usd">BTC</a>) becomes a key <a href="https://www.benzinga.com/markets/cryptocurrency/24/09/40927528/microstrategy-raises-875m-in-convertible-notes-plans-further-bitcoin-purchases">asset for corporate treasuries</a>, public companies are increasingly adopting innovative strategies to maximize their Bitcoin holdings.
What Happened: What began with MicroStrategy's (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MSTR#NASDAQ">MSTR</a>) decision to include Bitcoin in its corporate treasury has sparked a wave of similar moves by companies like Cathedra Bitcoin (OTC:<a class="ticker" href="https://www.benzinga.com/stock/CBTTF#OTC">CBTTF</a>), Metaplanet and Semler Scientific (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SMLR#NASDAQ">SMLR</a>).
The trend is redefining how firms manage their balance sheets and navigate economic uncertainty, <a href="https://www.coindesk.com/business/2024/09/19/maximizing-bitcoin-per-share-a-new-corporate-strategy/?utm_medium=referral&amp;utm_source=rss&amp;utm_campaign=headlines">according</a> to Coindesk.
MicroStrategy, led by Michael Saylor, stands at the forefront of this shift, recently expanding its Bitcoin portfolio to 244,800 coins, valued at nearly $9.45 billion. Saylor's approach, positioning Bitcoin as a hedge against inflation, has sent MicroStrategy's stock soaring—up 295% over the past year. 
The company's continued investments in Bitcoin, including a recent $700 million bond offering to finance more acquisitions, signal a long-term commitment to the cryptocurrency. 
Despite concerns over the stock's mixed technical outlook, Saylor remains bullish, stating that Bitcoin's role in corporate finance will only grow.
MicroStrategy's strategy has paved the way for other companies to follow suit. 
Cathedra Bitcoin, a publicly traded firm on the TSX Venture Exchange, has shifted its focus from Bitcoin mining to managing data centers, aiming to increase its Bitcoin holdings per share. 
As mining becomes more challenging due to Bitcoin halving, Cathedra's new approach allows it to generate sustainable cash flow while continuously acquiring more Bitcoin. 
"Going forward, we will make all capital allocation decisions with the intention of maximizing our shareholders' per-share Bitcoin holdings," the company said in a recent statement.
Metaplanet has taken a similar approach, focusing on growing its Bitcoin reserves month over month. 
The company's strategy has led to a 587% increase in its stock value this year, underscoring the market's positive response to this trend. 
CEO Simon Gerovich emphasized that prioritizing Bitcoin holdings has been a key driver of the company's recent success.
<figure class="wp-block-image size-full"><img loading="lazy" decoding="async" width="300" height="250" src="https://editorial-assets.benzinga.com/wp-content/uploads/2024/03/27091545/Benzinga-conference.gif" alt="Benzinga future of digital assets conference" class="wp-image-267246" /></figure>
Also Read: <a href="https://www.benzinga.com/markets/cryptocurrency/24/09/40937057/bitcoin-ethereum-etfs-see-over-50m-net-outflows-despite-feds-50-bps-rate-cut">Bitcoin, Ethereum ETFs See Over $50M Net Outflows Despite Fed&#8217;s 50 Bps Rate Cut</a>
Why It Matters: These moves reflect a broader shift toward using Bitcoin not only as a hedge against inflation but as a strategic asset to enhance shareholder value.
Companies like MicroStrategy and Cathedra are now leading the charge in what has been described as the <a href="https://www.benzinga.com/markets/cryptocurrency/24/09/40776328/microstrategys-bitcoin-strategy-has-outperformed-every-s-p-500-company-and-even-nvidia-sin">"maximize Bitcoin per share" strategy</a>.
This approach focuses on increasing Bitcoin reserves over time, leveraging the cryptocurrency's long-term growth potential.
MicroStrategy has further diversified its strategy by offering convertible bonds backed by Bitcoin collateral. 
These financial instruments, which offer a 1% interest rate, have attracted investors seeking lower-risk exposure to Bitcoin. 
"We're capturing a 50% premium or 50% type BTC yield on that up front," Saylor said, explaining how the bonds allow the company to acquire more Bitcoin while minimizing volatility.
The success of MicroStrategy's strategy has been hard to ignore. 
Since the company adopted Bitcoin in 2020, it has outperformed every company in the S&amp;P 500, achieving an average annual return of 44%. 
Saylor highlighted that even Nvidia, the index's top-performing stock, has been outpaced by MicroStrategy's Bitcoin-focused approach.
However, the strategy is not without risks. 
With mixed technical signals, including a bearish Moving Average Convergence Divergence (MACD) and a neutral Relative Strength Index (RSI), MicroStrategy's stock could face near-term volatility. 
The company's long-term success will depend on the broader adoption of Bitcoin and the potential for Bitcoin ETFs, which could bring the cryptocurrency <a href="https://www.benzinga.com/markets/cryptocurrency/24/09/40899629/microstrategy-doubles-down-on-bitcoin-can-the-stock-sustain-its-rally">further into the financial mainstream.</a>
As Bitcoin continues to reshape corporate strategies, these developments will be a focal point at Benzinga's <a href="https://www.benzinga.com/events/digital-assets/agenda/">Future of Digital Assets</a> event on Nov. 19.
Read Next: 
<ul>
<li><a href="https://www.benzinga.com/markets/cryptocurrency/24/09/40927528/microstrategy-raises-875m-in-convertible-notes-plans-further-bitcoin-purchases">MicroStrategy Raises $875M In Convertible Notes, Plans Further Bitcoin Purchases</a></li>
</ul>
Image: Shutterstock

MicroStrategy's Bitcoin Playbook Is Becoming A Hit Among Companies, But There's A Catch

A substantial insider activity was disclosed on August 27, as Murphy-Chutorian, CEO at Semler Scientific (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SMLR#NASDAQ">SMLR</a>), reported the exercise of a large sell of company stock options.
What Happened: A Form 4 filing with the <a href="https://www.sec.gov/Archives/edgar/data/0001554859/000110465924093474//Archives/edgar/data/1554859/000110465924093474/0001104659-24-093474-index.htm">U.S. Securities and Exchange Commission</a> on Tuesday revealed that Murphy-Chutorian, CEO at Semler Scientific in the Health Care sector, exercised stock options for 71,000 shares of SMLR stock. The exercise price of the options was $2.1 per share.
As of Wednesday morning, Semler Scientific shares are down by 1.2%, with a current price of $28.46. This implies that Murphy-Chutorian's 71,000 shares have a value of $1,871,843.
<h3>Get to Know Semler Scientific Better</h3>
Semler Scientific Inc is a United States based company that is engaged in providing technology solutions to improve the clinical effectiveness and efficiency of healthcare providers. It focuses on developing, manufacturing, and marketing proprietary products and services that assist customers, including insurance plans, physicians, and risk assessment groups, in evaluating and treating chronic diseases. The company markets its vascular-testing product under the QuantaFlo brand, which is a four-minute in-office blood flow test.
<h3>Key Indicators: Semler Scientific's Financial Health</h3>
Revenue Challenges: Semler Scientific's revenue growth over 3 months faced difficulties. As of 30 June, 2024, the company experienced a decline of approximately -22.25%. This indicates a decrease in top-line earnings. As compared to its peers, the revenue growth lags behind its industry peers. The company achieved a growth rate lower than the average among peers in Health Care sector.
Key Insights into Profitability Metrics:
<ul>
<li>
Gross Margin: The company excels with a remarkable gross margin of 91.32%, indicating superior cost efficiency and profitability compared to its industry peers.
</li>
<li>
Earnings per Share (EPS): Semler Scientific's EPS is below the industry average. The company faced challenges with a current EPS of 0.001584. This suggests a potential decline in earnings.
</li>
</ul>
Debt Management: Semler Scientific's debt-to-equity ratio is below the industry average at 0.0, reflecting a lower dependency on debt financing and a more conservative financial approach.
Financial Valuation Breakdown:
<ul>
<li>
Price to Earnings (P/E) Ratio: With a lower-than-average P/E ratio of 14.19, the stock indicates an attractive valuation, potentially presenting a buying opportunity.
</li>
<li>
Price to Sales (P/S) Ratio: With a higher-than-average P/S ratio of 3.63, Semler Scientific's stock is perceived as being overvalued in the market, particularly in relation to sales performance.
</li>
<li>
EV/EBITDA Analysis (Enterprise Value to its Earnings Before Interest, Taxes, Depreciation &amp; Amortization): The company's EV/EBITDA ratio of 8.34 trails industry averages, indicating a potential disparity in market valuation that could be advantageous for investors.
</li>
</ul>
Market Capitalization Analysis: The company's market capitalization surpasses industry averages, showcasing a dominant size relative to peers and suggesting a strong market position.
<a href="https://www.schwab.com/brokerage?aff=XEC">Now trade stocks online commission free with Charles Schwab, a trusted and complete investment firm.</a>
<h3>Why Pay Attention to Insider Transactions</h3>
Emphasizing the importance of a comprehensive approach, considering insider transactions is valuable, but it's crucial to evaluate them in conjunction with other investment factors.
Considering the legal perspective, an "insider" is defined as any officer, director, or beneficial owner holding more than ten percent of a company's equity securities, according to Section 12 of the Securities Exchange Act of 1934. This includes executives in the c-suite and major hedge funds. These insiders are mandated to disclose their transactions through a Form 4 filing, to be submitted within two business days of the transaction.
Pointing towards optimism, a company insider's new purchase signals their positive anticipation for the stock to rise.
Nevertheless, insider sells may not necessarily indicate a bearish view and can be influenced by various factors.
<h3>Essential Transaction Codes Unveiled</h3>
When it comes to transactions, <a href="https://www.benzinga.com/money/investing-tools">investors</a> tend to focus on those in the open market, detailed in Table I of the Form 4 filing. A P in Box 3 denotes a purchase, while S indicates a sale. Transaction code C signals the conversion of an option, and transaction code A denotes a grant, award, or other acquisition of securities from the company.
<a href="https://www.benzinga.com/sec/insider-trades/search/index?company_cik=0001554859">Check Out The Full List Of Semler Scientific's Insider Trades.</a>
This article was generated by Benzinga's automated content engine and reviewed by an editor.

Douglas Murphy-Chutorian At Semler Scientific Capitalizes: Options Exercised, Resulting In $1.87M

Company Sees Growing Institutional Adoption As A Positive Driver For Bitcoin Value And Stockholder Returns

Markets

CORRECTION: Semler Scientific Purchases 83 Additional Bitcoins For $5M, Bringing Total Holdings To 1,012 Bitcoins Acquired For $68M

Semler Scientific (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SMLR#NASDAQ">SMLR</a>) reported quarterly sales of $14.465 million which beat the analyst consensus estimate of $14.200 million by 1.87 percent. This is a 22.25 percent decrease over sales of $18.605 million the same period last year.

Semler Scientific Q2 Sales $14.465M Beat $14.200M Estimate

Semler Scientific's (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/SMLR#NYSE">SMLR</a>) short percent of float has risen 123.04% since its last report. The company recently reported that it has 477 thousand shares sold short, which is 8.52% of all regular shares that are available for trading. Based on its trading volume, it would take traders 1.32 days to cover their short positions on average.
<h3>Why Short Interest Matters</h3>
Short interest is the number of shares that have been sold short but have not yet been covered or closed out. <a href="https://www.benzinga.com/money/how-to-short-a-stock/">Short selling</a> is when a trader sells shares of a company they do not own, with the hope that the price will fall. Traders make money from short selling if the price of the stock falls and they lose if it rises.
Short interest is important to track because it can act as an indicator of market sentiment towards a particular stock. An increase in short interest can signal that investors have become more bearish, while a decrease in short interest can signal they have become more bullish.
See Also: <a href="https://www.benzinga.com/short-interest">List of the most shorted stocks</a>
<h3>Semler Scientific Short Interest Graph (3 Months)</h3>
<img src="https://www.benzinga.com/files/images/story/2024/1719000920_0.png" alt="short_fig" />
As you can see from the chart above the percentage of shares that are sold short for Semler Scientific has grown since its last report. This does not mean that the stock is going to fall in the near-term but traders should be aware that more shares are being shorted.
<h3>Comparing Semler Scientific's Short Interest Against Its Peers</h3>
Peer comparison is a popular technique amongst analysts and investors for gauging how well a company is performing. A company's peer is another company that has similar characteristics to it, such as industry, size, age, and financial structure. You can find a company's peer group by reading its 10-K, proxy filing, or by doing your own similarity analysis.
According to <a href="https://pro.benzinga.com/">Benzinga Pro</a>, Semler Scientific's peer group average for short interest as a percentage of float is 8.55%, which means the company has less short interest than most of its peers.
Did you know that increasing short interest can actually be bullish for a stock? <a href="https://www.benzinga.com/money/how-to-make-money-on-a-short-squeeze/">This post by Benzinga Money explains how you can profit from it.</a>
This article was generated by Benzinga's automated content engine and was reviewed by an editor.

Short Sellers

Short Ideas

Looking Into Semler Scientific's Recent Short Interest

<h3>Gainers</h3>
<ul>
<li>Seres Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MCRB#NASDAQ">MCRB</a>) stock moved upwards by 34.0% to $0.82 during Monday's regular session. The company's market cap stands at $124.5 million. </li>
<li>Renovaro (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/RENB#NASDAQ">RENB</a>) shares increased by 32.51% to $1.71. The market value of their outstanding shares is at $252.1 million. </li>
<li>Champions Oncology (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CSBR#NASDAQ">CSBR</a>) shares increased by 22.82% to $5.65. The company's market cap stands at $76.8 million. </li>
<li>Nanoviricides (AMEX:<a class="ticker" href="https://www.benzinga.com/stock/NNVC#AMEX">NNVC</a>) stock rose 22.02% to $3.26. The market value of their outstanding shares is at $38.4 million. </li>
<li>Semler Scientific (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SMLR#NASDAQ">SMLR</a>) stock moved upwards by 20.13% to $38.0. The market value of their outstanding shares is at $268.5 million. </li>
<li>TransCode Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/RNAZ#NASDAQ">RNAZ</a>) stock moved upwards by 18.63% to $1.3. The company's market cap stands at $8.6 million. </li>
</ul>
<h3>Losers</h3>
<ul>
<li>Sunshine Biopharma (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SBFM#NASDAQ">SBFM</a>) stock fell 35.6% to $0.36 during Monday's regular session. The company's market cap stands at $6.8 million. </li>
<li>Tharimmune (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/THAR#NASDAQ">THAR</a>) stock fell 31.74% to $3.55. The company's market cap stands at $2.7 million. </li>
<li>CNS Pharma (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CNSP#NASDAQ">CNSP</a>) stock decreased by 27.83% to $3.65. The company's market cap stands at $1.1 million. </li>
<li>Curis (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CRIS#NASDAQ">CRIS</a>) stock fell 19.58% to $7.11. The company's market cap stands at $41.9 million. </li>
<li>Skye Bioscience (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SKYE#NASDAQ">SKYE</a>) stock fell 15.0% to $9.3. The market value of their outstanding shares is at $261.0 million. </li>
<li>Novavax (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/NVAX#NASDAQ">NVAX</a>) shares decreased by 14.62% to $15.52. The company's market cap stands at $2.2 billion. 
See Also: <a href="http://www.benzinga.com/money/best-healthcare-stocks/" title="www.benzinga.com/money/best-healthcare-stocks/">www.benzinga.com/money/best-healthcare-stocks/</a></li>
</ul>
This article was generated by Benzinga's automated content engine and reviewed by an editor.

CNSP

CRIS

CSBR

MCRB

NNVC

NVAX

RENB

RNAZ

SBFM

SKYE

THAR

12 Health Care Stocks Moving In Monday's Intraday Session

Healthcare company Semler Scientific Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SMLR#NASDAQ">SMLR</a>) doubled down on its Bitcoin (CRYPTO: <a class="ticker" href="https://www.benzinga.com/quote/btc/usd">BTC</a>) investments by purchasing an additional $17 million of the world's largest digital asset.&nbsp;
What Happened: In a press release shared Thursday, the medical device manufacturer said it bought 247 Bitcoins for an aggregate value of $17 million. With the latest grab, the company's total Bitcoin holdings shot up to 828, worth more than $58 million at the prevailing price of the King Crypto. 
The company identified purchasing and holding Bitcoins as one of its two primary priorities, the other being expanding its healthcare operations, and said it will continue to buy more Bitcoins with cash.
Why It Matters: The firm's latest Bitcoin push comes just over a week after <a href="https://www.benzinga.com/markets/cryptocurrency/24/05/39042812/semler-scientific-28-after-adopting-bitcoin-as-primary-treasury-reserve-asset-whats-going-">it adopted Bitcoin as its primary treasury reserve asset</a>.&nbsp;
Higher-ups from the organization have consistently praised Bitcoin, calling it a "reasonable inflation hedge and safe haven amid global instability."&nbsp;
The move also underlined the evolving business strategy of publicly traded corporations trying to add Bitcoins to their portfolios.
The Michael Saylor-founded MicroStrategy remains the largest corporate holder of the prized digital currency, totaling 214,400, worth $15.8 billion, <a href="https://bitcointreasuries.com/">according </a>to bitcointreasuries.com.
Price Action: Shares of Semler Scientific closed 2.48% lower at $29.13 on Thursday, according to <a href="https://pro.benzinga.com/dashboard?_gl=1&#x2A;380nj0&#x2A;_ga&#x2A;MTEyOTAyOTcxMy4xNzEzMzY0NTYy&#x2A;_ga_V7ZK73W7N0&#x2A;MTcxNDk4MzIzMi42LjEuMTcxNDk4OTE0Ni4wLjAuMA..">data from Benzinga Pro</a>. Bitcoin was trading at $70,922.97 at the time of writing.
Read Next:<a href="https://www.benzinga.com/markets/cryptocurrency/24/06/39128955/roaring-kittys-new-social-post-pushes-gamestop-themed-crypto-by-200-kitty-themed-coins-sur"> </a><a href="https://www.benzinga.com/markets/cryptocurrency/24/06/39211057/jpmorgan-us-crypto-regulations-signal-opposition-to-cbdcs-and-non-compliant-stablecoins">JPMorgan: US Crypto Regulations Signal Opposition To CBDCs And Non-Compliant Stablecoins</a>

Another MicroStrategy In The Making? Semler Scientific Purchases 247 More Bitcoins To Push Total Portfolio Past $58M: 'We'll Continue To Buy More'

As of&nbsp;June 6, 2024, Semler holds a total of 828 bitcoins, which were acquired for an aggregate&nbsp;$57 million, inclusive of fees and expenses.&nbsp;

Semler Scientific Reports Purchase Of Additional 247 Bitcoins For Aggregate $17M Cash

ERIC SEMLER, Board Member at Semler Scientific (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SMLR#NASDAQ">SMLR</a>), reported acquisition of company stock options on May 29, according to a new SEC filing.
What Happened: In a Form 4 filing with the <a href="https://www.sec.gov/Archives/edgar/data/0001554859/000110465924066102//Archives/edgar/data/1554859/000110465924066102/0001104659-24-066102-index.htm">U.S. Securities and Exchange Commission</a> on Wednesday, SEMLER, Board Member at Semler Scientific, acquired stock options for 27,000 shares of SMLR. These options provide SEMLER with the right to purchase the company's stock at $23.32 per share.
During Thursday's morning session, Semler Scientific shares up by 3.13%, currently priced at $33.25. Considering the current price, SEMLER's 27,000 shares have a total value of $268,110.
<h3>All You Need to Know About Semler Scientific</h3>
Semler Scientific Inc is a United States based company that is engaged in providing technology solutions to improve the clinical effectiveness and efficiency of healthcare providers. It focuses on developing, manufacturing, and marketing proprietary products and services that assist customers, including insurance plans, physicians, and risk assessment groups, in evaluating and treating chronic diseases. The company markets its vascular-testing product under the QuantaFlo brand, which is a four-minute in-office blood flow test.
<h3>Semler Scientific: Financial Performance Dissected</h3>
Revenue Growth: Semler Scientific's revenue growth over a period of 3 months has faced challenges. As of 31 March, 2024, the company experienced a revenue decline of approximately -12.65%. This indicates a decrease in the company's top-line earnings. When compared to others in the Health Care sector, the company faces challenges, achieving a growth rate lower than the average among peers.
Profitability Metrics:
<ul>
<li>
Gross Margin: The company sets a benchmark with a high gross margin of 92.16%, reflecting superior cost management and profitability compared to its peers.
</li>
<li>
Earnings per Share (EPS): Semler Scientific's EPS is notably higher than the industry average. The company achieved a positive bottom-line trend with a current EPS of 0.88.
</li>
</ul>
Debt Management: Semler Scientific's debt-to-equity ratio is below industry norms, indicating a sound financial structure with a ratio of 0.0.
Market Valuation:
<ul>
<li>
Price to Earnings (P/E) Ratio: The P/E ratio of 11.58 is lower than the industry average, implying a discounted valuation for Semler Scientific's stock.
</li>
<li>
Price to Sales (P/S) Ratio: With a higher-than-average P/S ratio of 3.81, Semler Scientific's stock is perceived as being overvalued in the market, particularly in relation to sales performance.
</li>
<li>
EV/EBITDA Analysis (Enterprise Value to its Earnings Before Interest, Taxes, Depreciation &amp; Amortization): The company's EV/EBITDA ratio of 6.77 trails industry averages, indicating a potential disparity in market valuation that could be advantageous for investors.
</li>
</ul>
Market Capitalization Analysis: Reflecting a smaller scale, the company's market capitalization is positioned below industry averages. This could be attributed to factors such as growth expectations or operational capacity.
<a href="https://www.schwab.com/brokerage?aff=XEC">Now trade stocks online commission free with Charles Schwab, a trusted and complete investment firm.</a>
<h3>The Relevance of Insider Transactions</h3>
Investors should view insider transactions as part of a multifaceted analysis and not rely solely on them for decision-making.
Exploring the legal landscape, an "insider" is defined as any officer, director, or beneficial owner holding more than ten percent of a company's equity securities, as stipulated by Section 12 of the Securities Exchange Act of 1934. This encompasses executives in the c-suite and major hedge funds. These insiders are required to report their transactions through a Form 4 filing, which must be submitted within two business days of the transaction.
Highlighted by a company insider's new purchase, there's a positive anticipation for the stock to rise.
But, insider sells may not necessarily indicate a bearish view and can be motivated by various factors.
<h3>The Insider's Guide to Important Transaction Codes</h3>
When dissecting transactions, the focal point for <a href="https://www.benzinga.com/money/investing-tools">investors</a> is often those occurring in the open market, meticulously detailed in Table I of the Form 4 filing. A P in Box 3 denotes a purchase, while S signifies a sale. Transaction code C indicates the conversion of an option, and transaction code A denotes a grant, award, or other acquisition of securities from the company.
<a href="https://www.benzinga.com/sec/insider-trades/search/index?company_cik=0001554859">Check Out The Full List Of Semler Scientific's Insider Trades.</a>
This article was generated by Benzinga's automated content engine and reviewed by an editor.

Strategic Move: ERIC SEMLER Acquires Semler Scientific Stock Options Worth $268K

In a recent SEC filing, it was disclosed that William Chang, Director at Semler Scientific (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SMLR#NASDAQ">SMLR</a>), made a noteworthy acquisition of company stock options on May 29,.
What Happened: Chang, Director at Semler Scientific, engaged in a derivative transaction according to a Form 4 filing on Wednesday with the <a href="https://www.sec.gov/Archives/edgar/data/0001554859/000110465924066107//Archives/edgar/data/1554859/000110465924066107/0001104659-24-066107-index.htm">U.S. Securities and Exchange Commission</a>. This involved the acquisition of stock options for 27,000 shares of SMLR, providing the right to purchase the company's stock at an exercise price of $23.32 per share.
The Thursday morning market activity shows Semler Scientific shares up by 3.13%, trading at $33.25. This implies a total value of $268,110 for Chang's 27,000 shares.
<h3>All You Need to Know About Semler Scientific</h3>
Semler Scientific Inc is a United States based company that is engaged in providing technology solutions to improve the clinical effectiveness and efficiency of healthcare providers. It focuses on developing, manufacturing, and marketing proprietary products and services that assist customers, including insurance plans, physicians, and risk assessment groups, in evaluating and treating chronic diseases. The company markets its vascular-testing product under the QuantaFlo brand, which is a four-minute in-office blood flow test.
<h3>Semler Scientific: Financial Performance Dissected</h3>
Revenue Challenges: Semler Scientific's revenue growth over 3 months faced difficulties. As of 31 March, 2024, the company experienced a decline of approximately -12.65%. This indicates a decrease in top-line earnings. As compared to competitors, the company encountered difficulties, with a growth rate lower than the average among peers in the Health Care sector.
Interpreting Earnings Metrics:
<ul>
<li>
Gross Margin: The company sets a benchmark with a high gross margin of 92.16%, reflecting superior cost management and profitability compared to its peers.
</li>
<li>
Earnings per Share (EPS): The company excels with an EPS that surpasses the industry average. With a current EPS of 0.88, Semler Scientific showcases strong earnings per share.
</li>
</ul>
Debt Management: Semler Scientific's debt-to-equity ratio is below the industry average. With a ratio of 0.0, the company relies less on debt financing, maintaining a healthier balance between debt and equity, which can be viewed positively by investors.
Insights into Valuation Metrics:
<ul>
<li>
Price to Earnings (P/E) Ratio: Semler Scientific's P/E ratio of 11.58 is below the industry average, suggesting the stock may be undervalued.
</li>
<li>
Price to Sales (P/S) Ratio: With a higher-than-average P/S ratio of 3.81, Semler Scientific's stock is perceived as being overvalued in the market, particularly in relation to sales performance.
</li>
<li>
EV/EBITDA Analysis (Enterprise Value to its Earnings Before Interest, Taxes, Depreciation &amp; Amortization): With a lower-than-industry-average EV/EBITDA ratio of 6.77, Semler Scientific presents a potential value opportunity, as investors are paying less for each unit of EBITDA.
</li>
</ul>
Market Capitalization Perspectives: The company's market capitalization falls below industry averages, signaling a relatively smaller size compared to peers. This positioning may be influenced by factors such as perceived growth potential or operational scale.
<a href="https://www.schwab.com/brokerage?aff=XEC">Now trade stocks online commission free with Charles Schwab, a trusted and complete investment firm.</a>
<h3>Unmasking the Significance of Insider Transactions</h3>
Insightful as they may be, insider transactions should be considered alongside a thorough examination of other investment criteria.
Exploring the legal landscape, an "insider" is defined as any officer, director, or beneficial owner holding more than ten percent of a company's equity securities, as stipulated by Section 12 of the Securities Exchange Act of 1934. This encompasses executives in the c-suite and major hedge funds. These insiders are required to report their transactions through a Form 4 filing, which must be submitted within two business days of the transaction.
Highlighted by a company insider's new purchase, there's a positive anticipation for the stock to rise.
But, insider sells may not necessarily indicate a bearish view and can be motivated by various factors.
<h3>Exploring Key Transaction Codes</h3>
When analyzing transactions, <a href="https://www.benzinga.com/money/investing-tools">investors</a> tend to focus on those in the open market, detailed in Table I of the Form 4 filing. A P in Box 3 denotes a purchase,while S signifies a sale. Transaction code C signals the conversion of an option, and transaction code A denotes a grant, award, or other acquisition of securities from the company.
<a href="https://www.benzinga.com/sec/insider-trades/search/index?company_cik=0001554859">Check Out The Full List Of Semler Scientific's Insider Trades.</a>
This article was generated by Benzinga's automated content engine and reviewed by an editor.

Major Acquisition Alert: William Chang Acquires $268K In Semler Scientific Stock Options

Shares of Bank of Montreal (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/BMO#NYSE">BMO</a>) fell sharply during Wednesday's session after the company reported worse-than-expected <a href="https://www.benzinga.com/quote/BMO/earnings">second-quarter financial results</a>.
Bank of Montreal posted quarterly adjusted earnings of C$2.59 per share, missing market estimates of C$2.77 per share. The company's quarterly sales came in at C$7.988 billion missing expectations of C$8.046 billion, according to data from <a href="https://pro.benzinga.com/dashboard">Benzinga Pro</a>.
Bank of Montreal shares declined 7.1% to $89.32 on Wednesday.
Here are some other stocks moving in today&#8217;s mid-day session.
<h3 class="wp-block-heading">Gainers</h3>
<ul>
<li>ReShape Lifesciences Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/RSLS#NASDAQ">RSLS</a>) shares jumped 82.8% to $0.3799 a day after it received the nod from the U.S. Patent And Trademark Office to issue a patent for its obesity treatment.</li>
<li>Innovative Eyewear, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/LUCY#NASDAQ">LUCY</a>) shares jumped 56.1% to $0.64 after the company launched its Eddie Bauer Smart Eyewear collection.</li>
<li>Brand Engagement Network, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/BNAI#NASDAQ">BNAI</a>) climbed 41% to $1.7900 after the company announced a $4.95 million private placement and appointed Paul Chang to co-CEO.</li>
<li>Siyata Mobile Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SYTA#NASDAQ">SYTA</a>) gained 40% to $2.10. The company yesterday announced that it received an order from the City of Lancaster Public Utilities Department for its SD7 Push-to-Talk handsets, VK7 Vehicle Kits and related accessories.</li>
<li>AST SpaceMobile, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ASTS#NASDAQ">ASTS</a>) climbed 29% to $6.88 after the company announced a partnership with Verizon for direct-to-cellular AST SpaceMobile service when needed for Verizon customers.</li>
<li>Cheche Group Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CCG#NASDAQ">CCG</a>) shares gained 25.4% to $1.67. Cheche Group is expected to host a conference call to discuss first quarter 2024 results on Thursday, May 30.</li>
<li>Mustang Bio, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MBIO#NASDAQ">MBIO</a>) gained 25% to $0.2370.</li>
<li>Globavend Holdings Limited (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/GVH#NASDAQ">GVH</a>) jumped 23.5% to $1.89 after the company announced an MOU to acquire Top Logistics.</li>
<li>Ikena Oncology, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/IKNA#NASDAQ">IKNA</a>) gained 22.5% to $1.63 after the company announced it will discontinue development of IK-930 and evaluate strategic options for both the Company and its development pipeline.</li>
<li>Ooma, Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/OOMA#NYSE">OOMA</a>) rose 22.3% to $9.66 after the company reported better-than-expected first-quarter financial results and issued strong guidance for the second quarter.</li>
<li>Tantech Holdings Ltd (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/TANH#NASDAQ">TANH</a>) jumped 22% to $0.80. Tantech recently received a notice of non-compliance from the Nasdaq.</li>
<li>Chewy, Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/CHWY#NYSE">CHWY</a>) rose 21.5% to $20.54 following better-than-expected first-quarter earnings.</li>
<li>SOPHiA GENETICS SA (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SOPH#NASDAQ">SOPH</a>) gained 21.1% to $5.96.</li>
<li>Kintara Therapeutics, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/KTRA#NASDAQ">KTRA</a>) climbed 21% to $0.2290.</li>
<li>Surmodics, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SRDX#NASDAQ">SRDX</a>) gained 20.3% to $42.23 after the company announced it will be acquired by GTCR for $43 per share in cash for a total equity valuation of roughly $627 million.</li>
<li>Abercrombie &amp; Fitch Co. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/ANF#NYSE">ANF</a>) gained 15.9% to $176.57 following better-than-expected first-quarter financial results.</li>
<li>DICK&#8217;S Sporting Goods, Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/DKS#NYSE">DKS</a>) rose 15.8% to $225.87 as the company reported better-than-expected first-quarter FY24 earnings and raised the outlook.</li>
<li>Semler Scientific, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SMLR#NASDAQ">SMLR</a>) rose 14.8% to $33.28. The company recently announced that its board of directors adopted bitcoin as its primary treasury reserve asset.</li>
<li>Scorpius Holdings, Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/SCPX#NYSE">SCPX</a>) shares gained 14.2% to $0.1279 after gaining 6% on Tuesday.</li>
<li>Banzai International, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/BNZI#NASDAQ">BNZI</a>) gained 13.5% to $0.1989. Banzai, last week, announced the pricing of a $2.5 million public offering.</li>
<li>Neonode Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/NEON#NASDAQ">NEON</a>) jumped 12.9% to $3.2746.</li>
<li>Gyre Therapeutics, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/GYRE#NASDAQ">GYRE</a>) jumped 12.3% to $11.40. Gyre Therapeutics announced expected addition to the Russell 2000&#xAE; and Russell 3000&#xAE; Indexes.</li>
<li>Immunovant, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/IMVT#NASDAQ">IMVT</a>) rose 11.3% to $31.66.</li>
<li>Ascent Solar Technologies, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ASTI#NASDAQ">ASTI</a>) gained 11.2% to $0.1660 following a 3% decline on Tuesday.</li>
<li>Box, Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/BOX#NYSE">BOX</a>) rose 9.1% to $27.30 as the company reported its first-quarter financial results.</li>
<li>Titan Machinery Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/TITN#NASDAQ">TITN</a>) gained 8.2% to $19.18.</li>
</ul>
<h3 class="wp-block-heading">Losers</h3>
<ul>
<li>Faraday Future Intelligent Electric Inc (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/FFIE#NASDAQ">FFIE</a>) fell 38.8% to $0.7232. Faraday Future's annual report for fiscal year 2023 showed a revenue of $0.8 million, significantly below analyst estimates of $2.59 million. While the net loss narrowed from $602 million in 2022 to $432 million in 2023, it still paints a concerning financial picture.</li>
<li>AERWINS Technologies Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AWIN#NASDAQ">AWIN</a>) shares fell 37% to $5.74. AERWINS Technologies shares jumped 143% on Tuesday after the company reported a year-over-year increase in first-quarter EPS results.</li>
<li>SOBR Safe, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SOBR#NASDAQ">SOBR</a>) shares fell 32% to $0.2889 after jumping 84% on Monday.</li>
<li>Cue Health Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/HLTH#NASDAQ">HLTH</a>) shares dipped 29.1% to $0.0643 after the company announced that it filed voluntary petitions under Chapter 7 of the U.S. Bankruptcy Code in the District of Delaware to pursue a wind down of its business.</li>
<li>Sharps Technology, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/STSS#NASDAQ">STSS</a>) shares declined 26.4% to $0.3810 after surging 141% on Tuesday. In an exchange filing, the company said it has entered into a series of agreements with Nephron SC and Nephron Sterile Compounding Centers.</li>
<li>Fangdd Network Group Ltd. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/DUO#NASDAQ">DUO</a>) fell 23.8% to $0.8073.</li>
<li>Genetic Technologies Limited (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/GENE#NASDAQ">GENE</a>) declined 18.4% to $1.7301. GTG launched revolutionary geneType test covering 100% risk of breast and ovarian cancer.</li>
<li>CN Energy Group. Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CNEY#NASDAQ">CNEY</a>) dipped 18% to $0.51.</li>
<li>Predictive Oncology Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/POAI#NASDAQ">POAI</a>) fell 17.6% to $1.72. Predictive Oncology shares surged 31% on Tuesday after the company announced results from its ovarian caner study with UPMC Magee-Womens Hospital.</li>
<li>Maravai LifeSciences Holdings, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MRVI#NASDAQ">MRVI</a>) dropped 15.3% to $9.15.</li>
<li>American Airlines Group Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AAL#NASDAQ">AAL</a>) shares declined 15.3% to $11.38 after the company announced the departure of its executive vice president and lowered guidance for the second quarter.</li>
<li>Bank OZK (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/OZK#NASDAQ">OZK</a>) fell 15% to $39.30 after Citigroup downgraded the stock from Buy to Sell and lowered its price target from $57 to $37.</li>
<li>Crown ElectroKinetics Corp. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CRKN#NASDAQ">CRKN</a>) dipped 15% to $0.0909.</li>
<li>Onfolio Holdings, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ONFO#NASDAQ">ONFO</a>) shares fell 14.3% to $1.13 in pre-market trading after jumping around 36% on Tuesday. Onfolio Holdings, last week, posted a quarterly loss of 14 cents per share.</li>
<li>Veru Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/VERU#NASDAQ">VERU</a>) fell 13.1% to $0.9644.</li>
<li>Telephone and Data Systems, Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/TDS#NYSE">TDS</a>) fell 9.3% to $17.31. JP Morgan analyst Sebastiano Petti maintained Telephone and Data with an Overweight and lowered the price target from $36 to $34.</li>
<li>Toast, Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/TOST#NYSE">TOST</a>) fell 6.4% to $23.81.</li>
<li>Advance Auto Parts, Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/AAP#NYSE">AAP</a>) fell 5.5% to $66.28 following quarterly earnings.</li>
<li>CAVA Group, Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/CAVA#NYSE">CAVA</a>) shares declined 4.2% to $78.92 following first-quarter results.</li>
</ul>
Now Read This: <a href="https://www.benzinga.com/trading-ideas/long-ideas/24/05/39062044/amazon-target-diamondback-energy-and-more-on-cnbcs-final-trades">Amazon, Target, Diamondback Energy And More On CNBC&#8217;s &#8216;Final Trades</a>&#8216;

Intraday Update

ASTI

ASTS

AWIN

BNAI

BNZI

CAVA

CHWY

CNEY

CRKN

FFIE

GENE

GYRE

HLTH

IKNA

IMVT

Kintara Therapeutics, Inc. - Common Stock

KTRA

LUCY

MBIO

MRVI

NEON

ONFO

OOMA

POAI

RSLS

SCPX

SOBR

SOPH

SRDX

STSS

SYTA

TANH

TITN

TOST

VERU

Why Bank of Montreal Shares Are Trading Lower By Around 7%? Here Are Other Stocks Moving In Wednesday's Mid-Day Session

U.S. stocks were lower, with the Dow Jones index falling more than 300 points on Wednesday.
Shares of HEICO Corporation (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/HEI#NYSE">HEI</a>) rose sharply during Wednesday's session following a <a href="https://www.benzinga.com/quote/HEI/earnings">second-quarter earnings beat.</a>
Heico posted quarterly GAAP earnings of 88 cents per share, beating market estimates of 81 cents per share. The company's quarterly sales came in at $955.395 million versus expectations of $951.206 million, according to data from <a href="https://pro.benzinga.com/dashboard">Benzinga Pro</a>.
HEICO shares gained 4.6% to $221.76 on Wednesday.
Here are some other big stocks recording gains in today's session.
<ul>
<li>AST SpaceMobile, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ASTS#NASDAQ">ASTS</a>) shares gained 29% to $6.88 after the company announced a partnership with Verizon for direct-to-cellular AST SpaceMobile service when needed for Verizon customers.</li>
<li>Ooma, Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/OOMA#NYSE">OOMA</a>) gained 22.3% to $9.66 after the company reported better-than-expected first-quarter financial results and issued strong guidance for the second quarter.</li>
<li>SOPHiA GENETICS SA (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SOPH#NASDAQ">SOPH</a>) gained 21.1% to $5.96.</li>
<li>Surmodics, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SRDX#NASDAQ">SRDX</a>) climbed 20.3% to $42.23 after the company announced it will be acquired by GTCR for $43 per share in cash for a total equity valuation of roughly $627 million.</li>
<li>Abercrombie &amp; Fitch Co. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/ANF#NYSE">ANF</a>) shares rose 15.9% to $176.57 following better-than-expected first-quarter financial results.</li>
<li>DICK&#8217;S Sporting Goods, Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/DKS#NYSE">DKS</a>) gained 15.8% to $225.87 as the company reported better-than-expected first-quarter FY24 earnings and raised the outlook.</li>
<li>Semler Scientific, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SMLR#NASDAQ">SMLR</a>) surged 14.8% to $33.28. The company recenyly announced that its board of directors adopted bitcoin as its primary treasury reserve asset.</li>
<li>Gyre Therapeutics, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/GYRE#NASDAQ">GYRE</a>) jumped 12.3% to $11.40. Gyre Therapeutics announced expected addition to the Russell 2000&#xAE; and Russell 3000&#xAE; Indexes.</li>
<li>Immunovant, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/IMVT#NASDAQ">IMVT</a>) gained 11.3% to $31.66.</li>
<li>Hello Group Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MOMO#NASDAQ">MOMO</a>) jumped 9.8% to $5.32.</li>
<li>Marathon Oil Corporation (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/MRO#NYSE">MRO</a>) jumped 9.6% to $29.00 after ConocoPhillips announced it will acquire the company.</li>
<li>Box, Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/BOX#NYSE">BOX</a>) jumped 9.1% to $27.30 as the company reported its first-quarter financial results.</li>
<li>N-able, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/NABL#NASDAQ">NABL</a>) gained 9% to $13.74 following a report suggesting the company is running a sale process amid takeover interest.</li>
<li>Titan Machinery Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/TITN#NASDAQ">TITN</a>) rose 8.2% to $19.18.</li>
<li>Daqo New Energy Corp. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/DQ#NYSE">DQ</a>) gained 8% to $21.53.</li>
<li>JinkoSolar Holding Co., Ltd. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/JKS#NYSE">JKS</a>) jumped 4.9% to $29.78.</li>
</ul>
Now Read This: <a href="https://www.benzinga.com/trading-ideas/long-ideas/24/05/39062044/amazon-target-diamondback-energy-and-more-on-cnbcs-final-trades">Amazon, Target, Diamondback Energy And More On CNBC&#8217;s &#8216;Final Trades</a>&#8216;

MOMO

NABL

Heico Posts Upbeat Earnings, Joins Surmodics, Abercrombie & Fitch And Other Big Stocks Moving Higher On Wednesday

<h3>Gainers</h3>
<ul>
<li>Sharps Technology (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/STSS#NASDAQ">STSS</a>) stock rose 140.0% to $0.51 during Tuesday's regular session. The company's market cap stands at $8.0 million. </li>
<li>Insmed (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/INSM#NASDAQ">INSM</a>) stock moved upwards by 112.72% to $46.8. The company's market cap stands at $6.9 billion. </li>
<li>Calliditas Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CALT#NASDAQ">CALT</a>) shares moved upwards by 69.26% to $37.95. The company's market cap stands at $1.0 billion. The company's, Q1 earnings came out 3 days ago. </li>
<li>Predictive Oncology (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/POAI#NASDAQ">POAI</a>) shares rose 36.54% to $2.14. The company's market cap stands at $8.7 million. </li>
<li>Semler Scientific (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SMLR#NASDAQ">SMLR</a>) stock moved upwards by 28.55% to $29.98. The company's market cap stands at $211.8 million. </li>
<li>Exicure (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/XCUR#NASDAQ">XCUR</a>) shares rose 23.02% to $0.41. The market value of their outstanding shares is at $3.5 million. </li>
</ul>
<h3>Losers</h3>
<ul>
<li>Applied DNA Sciences (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/APDN#NASDAQ">APDN</a>) stock decreased by 68.9% to $0.62 during Tuesday's regular session. </li>
<li>Innovative Eyewear (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/LUCY#NASDAQ">LUCY</a>) shares fell 39.58% to $0.59. The company's market cap stands at $10.3 million. </li>
<li>Summit Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SMMT#NASDAQ">SMMT</a>) shares declined by 28.85% to $2.4. The market value of their outstanding shares is at $1.6 billion. </li>
<li>Akanda (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AKAN#NASDAQ">AKAN</a>) shares declined by 18.5% to $3.35. The market value of their outstanding shares is at $3.0 million. </li>
<li>G1 Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/GTHX#NASDAQ">GTHX</a>) shares fell 17.85% to $3.36. The company's market cap stands at $175.6 million. </li>
<li>60 Degrees (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SXTP#NASDAQ">SXTP</a>) stock declined by 17.41% to $0.26. The market value of their outstanding shares is at $3.1 million. 
See Also: <a href="http://www.benzinga.com/money/best-healthcare-stocks/" title="www.benzinga.com/money/best-healthcare-stocks/">www.benzinga.com/money/best-healthcare-stocks/</a></li>
</ul>
This article was generated by Benzinga's automated content engine and reviewed by an editor.

AKAN

APDN

CALT

GTHX

INSM

SMMT

SXTP

XCUR

Semler Scientific, Inc.&nbsp;(NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SMLR#NASDAQ">SMLR</a>) shares are trading higher on Tuesday after the company announced that its board of directors adopted&nbsp;<a target="_blank" href="https://www.benzinga.com/movers" rel="noreferrer noopener">bitcoin as its primary treasury reserve asset</a>.
In addition, Semler Scientific announced that it&nbsp;had&nbsp;purchased 581 bitcoins for an aggregate amount of&nbsp;$40 million,&nbsp;i<a target="_blank" href="https://www.benzinga.com/pressreleases/24/05/n39038342/semler-scientific-announces-bitcoin-treasury-strategy" rel="noreferrer noopener">nclusive of&nbsp;fees and expenses.</a>
Bitcoin will serve as the primary treasury holding on an ongoing basis, pending&nbsp;market conditions and Semler Scientific&#8217;s anticipated cash requirements.
&#8220;Bitcoin&nbsp;is now a major asset class with more than&nbsp;$1 trillion&nbsp;of market value. We believe it has unique characteristics as a scarce and finite asset that can serve as a reasonable inflation hedge and&nbsp;safe&nbsp;haven amid global instability,&#8221; said&nbsp;Eric Semler, Semler Scientific&#8217;s chairman.&nbsp;
&#8220;Given the gap in value between gold and&nbsp;bitcoin, we believe that&nbsp;bitcoin&nbsp;has the potential to generate outsize returns as it gains increasing acceptance as digital gold,&#8221; Semler added.
Semler Scientific&#8217;s board and senior management have spent substantial time examining potential uses of cash, including acquisitions. &#8220;After studying various alternatives, we decided that holding&nbsp;bitcoin&nbsp;would be the best use of our excess cash,&#8221; said Semler.&nbsp;
In conjunction with its&nbsp;bitcoin&nbsp;treasury strategy, Semler Scientific will continue to focus on its core medical products and services.&nbsp;
Semler Scientific plans to assess its surplus cash while QuantaFlo sales generate revenue and free cash flow.&nbsp;
&#8220;We remain dedicated to our customers and our goal of operating a growing and profitable healthcare company,&#8221;&nbsp;said&nbsp;Doug Murphy-Chutorian, Semler Scientific&#8217;s chief executive officer.
Price Action:&nbsp;SMLR shares are trading higher by 28% to $29.85 at last check Tuesday.
Read Next: <a href="https://www.benzinga.com/markets/equities/24/05/39021107/donald-trump-floats-idea-of-bringing-back-adviser-peter-navarro-for-potential-second-term-despit" target="_blank" rel="noreferrer noopener">Donald Trump Floats Idea Of Bringing Back Adviser Peter Navarro For Potential Second Term Despite Prison Sentence: &#8216;I Would Absolutely Have Peter Back&#8217;</a>
Image via Shutterstock

Equities

Health Care

General

Semler Scientific +28% After Adopting Bitcoin As Primary Treasury Reserve Asset: What's Going On?

A New Look At Corporate Treasury Strategy

Semler Scientific buys additional 83 Bitcoins

Shares of Semler Scientific ($SMLR) are little changed today after the medical technology company bought another 83 Bitcoin (BTC-USD) for $5 millio...

Semler Scientific (NASDAQ:SMLR) Buys More Bitcoin, Shares Flat

Semler Scientific ( ($SMLR) ) has issued an update. At Semler Scientific, Inc.'s Annual Meeting, stockholders approved the 2024 Stock Option and In...

Semler Scientific Shareholders Shape Governance and Strategy

Semler Scientific Q3 2024 Earnings Preview

Semler Scientific GAAP EPS of $0.72 beats by $0.35, revenue of $13.5M beats by $0.4M

Semler Scientific, Inc. (SMLR) Q3 2024 Earnings Call Transcript

Semler Scientific ( ($SMLR) ) has released its Q3 earnings. Here is a breakdown of the information Semler Scientific presented to its investors. Se...

Semler Scientific Reports Q3 2024 Earnings and Bitcoin Strategy

Semler Scientific: Topline Challenges Persist, While New Treasury Strategy Prompts A Shift

Bitcoin's Rally: The Tulips Have Done It Again

AAPL

ARLP

BSQKZ

FBTC

GBTC

IBIT

TSLA

Small Cap

Press Releases

Semler Scientific to Report First Quarter Financial Results and Host Conference Call on May 7, 2024

Semler Scientific® Reports First Quarter 2024 Financial Results

Semler Scientific® Announces Bitcoin Treasury Strategy

Semler Scientific® Announces Additional Bitcoin Purchases

Semler Scientific to Report Second Quarter and First Half of 2024 Financial Results and Host Conference Call on August 5, 2024

Semler Scientific® Reports Second Quarter 2024 Financial Results and Additional Bitcoin Purchases

Fintech

Semler Scientific Announces Additional Bitcoin Purchases

Kaskela Law LLC Announces Shareholder Investigation of Semler Scientific, Inc. (NASDAQ: SMLR) and Encourages Investors to Contact the Firm

Semler Scientific to Report Third Quarter and First Nine Months of 2024 Financial Results, Provide an Update on Bitcoin Holdings and Host Conference Call on November 4, 2024

Semler Scientific® Reports Third Quarter 2024 Financial Results and Additional Bitcoin Purchases

Comments

Semler Scientific

Semler Scientific (SMLR) Options

No option chain data available. Please try again later

Notizie

PARTENAIRE / CONTRIBUTEUR

BENZINGA MONDIAL